Ablynx

Ablynx (EBR:ABLX) Publication of transparency notifications in accordance with Article 14 of the Belgian Act of 2 May 2007 regarding the publication of major shareholdings

Ablynx (EBR:ABLX) GHENT, Belgium, 20 October, 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that a consortium, comprising DG Infra+, B.S.I. and Foremost Immo, has committed to invest in the development of a 10,000 m² cutting-edge laboratory facility (the Bio-Accelerator) on the Technologiepark in Zwijnaarde, Ghent. This facility will be close to Ablynx's existing facilities and the company has secured the right to use 70% of the capacity of the Bio-Accelerator, which is expected to be completed by mid-2010.

Ablynx (EBR:ABLX) GHENT, Belgium, 10 October, 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today it has successfully generated Nanobodies® against several GPCR receptors. Furthermore, Ablynx will present during its R&D update in Ghent today, its new preclinical development programme ALX-0141, a Nanobody® against Receptor Activator for Nuclear Factor kappa B Ligand (RANKL), an important target for bone disorders such as osteoporosis. The Company also provided an update on the significant progress made of its Nanobody® therapeutic pipeline and Nanobody® technology platform.

Ablynx (EBR:ABLX) GHENT, Belgium, 3 October 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has been awarded a grant worth €1.8 million by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).

Ablynx (EBR:ABLX) GHENT, Belgium, 12 September 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, published today the information in accordance with Articles 15, 18 and 29 of the Belgian Act of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Act").

Ablynx (EBR:ABLX) Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies® against two targets in oncology and immunology and equally share the resulting profits

Ablynx (EBR:ABLX) GHENT, Belgium, 28 August 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today its results for the six month period ending 30 June, 2008, which have been prepared in accordance with the IAS 34 'Interim Financial Reporting' as adopted by the European Union.

Ablynx (EBR:ABLX) GHENT, Belgium, 21 August 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, will announce its half year results for 2008 on 28 August 2008.

Ablynx (EBR:ABLX) GHENT, Belgium, 21 August 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that the Alzheimer's disease collaboration with Boehringer Ingelheim was proceeding well and therefore the research funding has been extended for another year.